Abstract

Magnetic Resonance Spectroscopy (MRS) is a non-invasive diagnostic and is the neuroimaging method of choice for the noninvasive monitoring of brain metabolism in patients with glioma tumors due to the enormous amount of information it yields regarding the morphologic features of the lesion and surrounding parenchyma. The most prevalent metabolites in the MRS spectrum are N-acetylasparate (NAA), total-Cholinecontaining metabolites (Cho), Lactate (Lac), Mobile Lipids (Lip), Creatine (Cre), Glutamate (Glu), Glutamine (Gin; the glutamate and glutamine signals cannot always be resolved and studies will then refer to their composite Glx peak), Myo-Inositol (mlns), Glycine (Gly), Glutathione (GSH) and 2-Hydroxyglutarate (2-HG). Personalized medicine using MRS can be used an understanding of the various physiological basic and mechanism of the metabolic signatures obtained from different types of tumors, and the specificity of the technique. Finally, establishment basis of physiological characteristics of the metabolites in various types of brain tumors, and the clinical utility of MRS as an additional and confirming diagnostic tool could improvement processes include fact and correct primary differential diagnosis therapeutic planning, and the assessment of response to treatment. © Medwell Journals, 2016.